Cargando…

Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance

INTRODUCTION: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance (CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild d...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamitsos, Theodoros D, Ntusi, Ntobeko AB, Francis, Jane M, Holloway, Cameron J, Myerson, Saul G, Neubauer, Stefan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996376/
https://www.ncbi.nlm.nih.gov/pubmed/21080924
http://dx.doi.org/10.1186/1532-429X-12-66
_version_ 1782193196546129920
author Karamitsos, Theodoros D
Ntusi, Ntobeko AB
Francis, Jane M
Holloway, Cameron J
Myerson, Saul G
Neubauer, Stefan
author_facet Karamitsos, Theodoros D
Ntusi, Ntobeko AB
Francis, Jane M
Holloway, Cameron J
Myerson, Saul G
Neubauer, Stefan
author_sort Karamitsos, Theodoros D
collection PubMed
description INTRODUCTION: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance (CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild decrease in systolic blood pressure (SBP). Whether an increase in the rate of adenosine infusion would improve peripheral and, likely, coronary vasodilatation in those patients is unknown. The aim of the present study was to assess the tolerance and safety of a high-dose adenosine protocol in patients with inadequate haemodynamic response to the standard adenosine protocol when undergoing CMR perfusion imaging. METHODS: 98 consecutive patients with known or suspected coronary artery disease (CAD) underwent CMR perfusion imaging at 1.5 Tesla. Subjects were screened for contraindications to adenosine, and an electrocardiogram was performed prior to the scan. All patients initially received the standard adenosine protocol (140 mcg/kg/min for at least 3 minutes). If the haemodynamic response was inadequate (HR increase < 10 bpm or SBP decrease < 10 mmHg) then the infusion rate was increased up to a maximum of 210 mcg/kg/min (maximal infusion duration 7 minutes). RESULTS: All patients successfully completed the CMR scan. Of a total of 98 patients, 18 (18%) did not demonstrate evidence of a significant increase in HR or decrease in SBP under the standard adenosine infusion rate. Following the increase in the rate of infusion, 16 out of those 18 patients showed an adequate haemodynamic response. One patient of the standard infusion group and two patients of the high-dose group developed transient advanced AV block. Significantly more patients complained of chest pain in the high-dose group (61% vs. 29%, p = 0.009). On multivariate analysis, age > 65 years and ejection fraction < 57% were the only independent predictors of blunted haemodynamic responsiveness to adenosine. CONCLUSIONS: A substantial number of patients do not show adequate peripheral haemodynamic response to standard-dose adenosine stress during perfusion CMR imaging. Age and reduced ejection fraction are predictors of inadequate response to standard dose adenosine. A high-dose adenosine protocol (up to 210 mcg/kg/min) is well tolerated and results in adequate haemodynamic response in nearly all patients.
format Text
id pubmed-2996376
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29963762010-12-03 Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance Karamitsos, Theodoros D Ntusi, Ntobeko AB Francis, Jane M Holloway, Cameron J Myerson, Saul G Neubauer, Stefan J Cardiovasc Magn Reson Research INTRODUCTION: Adenosine is the most widely used vasodilator stress agent for Cardiovascular Magnetic Resonance (CMR) perfusion studies. With the standard dose of 140 mcg/kg/min some patients fail to demonstrate characteristic haemodynamic changes: a significant increase in heart rate (HR) and mild decrease in systolic blood pressure (SBP). Whether an increase in the rate of adenosine infusion would improve peripheral and, likely, coronary vasodilatation in those patients is unknown. The aim of the present study was to assess the tolerance and safety of a high-dose adenosine protocol in patients with inadequate haemodynamic response to the standard adenosine protocol when undergoing CMR perfusion imaging. METHODS: 98 consecutive patients with known or suspected coronary artery disease (CAD) underwent CMR perfusion imaging at 1.5 Tesla. Subjects were screened for contraindications to adenosine, and an electrocardiogram was performed prior to the scan. All patients initially received the standard adenosine protocol (140 mcg/kg/min for at least 3 minutes). If the haemodynamic response was inadequate (HR increase < 10 bpm or SBP decrease < 10 mmHg) then the infusion rate was increased up to a maximum of 210 mcg/kg/min (maximal infusion duration 7 minutes). RESULTS: All patients successfully completed the CMR scan. Of a total of 98 patients, 18 (18%) did not demonstrate evidence of a significant increase in HR or decrease in SBP under the standard adenosine infusion rate. Following the increase in the rate of infusion, 16 out of those 18 patients showed an adequate haemodynamic response. One patient of the standard infusion group and two patients of the high-dose group developed transient advanced AV block. Significantly more patients complained of chest pain in the high-dose group (61% vs. 29%, p = 0.009). On multivariate analysis, age > 65 years and ejection fraction < 57% were the only independent predictors of blunted haemodynamic responsiveness to adenosine. CONCLUSIONS: A substantial number of patients do not show adequate peripheral haemodynamic response to standard-dose adenosine stress during perfusion CMR imaging. Age and reduced ejection fraction are predictors of inadequate response to standard dose adenosine. A high-dose adenosine protocol (up to 210 mcg/kg/min) is well tolerated and results in adequate haemodynamic response in nearly all patients. BioMed Central 2010-11-16 /pmc/articles/PMC2996376/ /pubmed/21080924 http://dx.doi.org/10.1186/1532-429X-12-66 Text en Copyright ©2010 Karamitsos et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Karamitsos, Theodoros D
Ntusi, Ntobeko AB
Francis, Jane M
Holloway, Cameron J
Myerson, Saul G
Neubauer, Stefan
Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
title Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
title_full Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
title_fullStr Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
title_full_unstemmed Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
title_short Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
title_sort feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2996376/
https://www.ncbi.nlm.nih.gov/pubmed/21080924
http://dx.doi.org/10.1186/1532-429X-12-66
work_keys_str_mv AT karamitsostheodorosd feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance
AT ntusintobekoab feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance
AT francisjanem feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance
AT hollowaycameronj feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance
AT myersonsaulg feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance
AT neubauerstefan feasibilityandsafetyofhighdoseadenosineperfusioncardiovascularmagneticresonance